Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas - PubMed (original) (raw)
doi: 10.1016/j.ccr.2005.03.019.
Shigeyuki Oba, Yohko Nakamura, Eriko Isogai, Setsuko Kaneko, Atsuko Nakagawa, Takahiro Hirata, Hiroyuki Kubo, Takeshi Goto, Saichi Yamada, Yasuko Yoshida, Misa Fuchioka, Shin Ishii, Akira Nakagawara
Affiliations
- PMID: 15837623
- DOI: 10.1016/j.ccr.2005.03.019
Free article
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas
Miki Ohira et al. Cancer Cell. 2005 Apr.
Free article
Abstract
To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10(-4)), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.
Similar articles
- Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A. Schramm A, et al. Oncogene. 2005 Nov 24;24(53):7902-12. doi: 10.1038/sj.onc.1208936. Oncogene. 2005. PMID: 16103881 - Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A. Tomioka N, et al. Oncogene. 2008 Jan 17;27(4):441-9. doi: 10.1038/sj.onc.1210661. Epub 2007 Jul 16. Oncogene. 2008. PMID: 17637744 - Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M. Oberthuer A, et al. Clin Cancer Res. 2008 Oct 15;14(20):6590-601. doi: 10.1158/1078-0432.CCR-07-4377. Clin Cancer Res. 2008. PMID: 18927300 - A review of DNA microarray analysis of human neuroblastomas.
Ohira M, Oba S, Nakamura Y, Hirata T, Ishii S, Nakagawara A. Ohira M, et al. Cancer Lett. 2005 Oct 18;228(1-2):5-11. doi: 10.1016/j.canlet.2005.01.054. Cancer Lett. 2005. PMID: 15936139 Review. - Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Warnat P, et al. BMC Cancer. 2007 May 25;7:89. doi: 10.1186/1471-2407-7-89. BMC Cancer. 2007. PMID: 17531100 Free PMC article. Review.
Cited by
- Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation.
Banerjee D, Bagchi S, Liu Z, Chou HC, Xu M, Sun M, Aloisi S, Vaksman Z, Diskin SJ, Zimmerman M, Khan J, Gryder B, Thiele CJ. Banerjee D, et al. Nat Commun. 2024 Apr 23;15(1):3432. doi: 10.1038/s41467-024-47166-y. Nat Commun. 2024. PMID: 38653778 Free PMC article. - Comparative epigenomics by machine learning approach for neuroblastoma.
Sugino RP, Ohira M, Mansai SP, Kamijo T. Sugino RP, et al. BMC Genomics. 2022 Dec 27;23(1):852. doi: 10.1186/s12864-022-09061-y. BMC Genomics. 2022. PMID: 36572864 Free PMC article. - Chromosome instability in neuroblastoma: A pathway to aggressive disease.
Paolini L, Hussain S, Galardy PJ. Paolini L, et al. Front Oncol. 2022 Oct 20;12:988972. doi: 10.3389/fonc.2022.988972. eCollection 2022. Front Oncol. 2022. PMID: 36338721 Free PMC article. Review. - Deep analysis of neuroblastoma core regulatory circuitries using online databases and integrated bioinformatics shows their pan-cancer roles as prognostic predictors.
Jahangiri L, Pucci P, Ishola T, Pereira J, Cavanagh ML, Turner SD. Jahangiri L, et al. Discov Oncol. 2021 Nov 29;12(1):56. doi: 10.1007/s12672-021-00452-3. Discov Oncol. 2021. PMID: 35201514 Free PMC article. - NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.
Takatori A, Hossain MS, Ogura A, Akter J, Nakamura Y, Nakagawara A. Takatori A, et al. Front Oncol. 2021 Jun 25;11:669667. doi: 10.3389/fonc.2021.669667. eCollection 2021. Front Oncol. 2021. PMID: 34277416 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical